Replies to post #23608 on Avid Bioservices Inc (CDMO)

[Green grine]

Jess -
During the past fiscal year, we have had discussions with
several parties interested in either partnering or acquiring Avid. Given our anticipated drug development plans over the next several years, we believe maintaining our own facility will result in significant cost savings. Such savings must be considered when reviewing a proposal to partner or sell Avid.
Provided that the right opportunity and financial terms are presented to us and further provided that the manufacturing needs of our customers and Peregrine are not jeopardized, the Company would be open to a possible strategic transaction
related to Avid.

http://sec.edgar-online.com/2004/07/14/0001019687-04-001537/Section2.asp

Green

[pharmboy21]

Jessme,

"Any data is still just animal data correct?"
Yes, and you may be right as far as its immediate impact on the pps. But, I think what you are missing is the importance of outside validation for our technology. Even if they aren't mentioning bavi by name, these papers that Jazz mentions are important because they are painting the picture as to why PS may be a hugely important mechanism in disease. What jazz is leading to is that these upcomg papers from Duke will involve further validation, and information concerning TARGETING PS, and hopefully, it will show how incredibly promising this is going to be. I am not aware of anyone else who is involved in targeting PS with a proven safe antibody, which means from time of discovery to putting an antibody through animal studies, phase 1, phase 2 trials means that PPHM has a huge leg up on anyone else that wishes to follow suit...meaning if the technology continues to prove itself, especially with the upcoming phase 2 breast cancer data, then we are sitting on a very valuable platform. Add on top of that the fact that we know it should be effective in any solid tumor (vs many antibodies that are specific for one type of cancer, then even specific subtypes of cancer, ex HER-2 + breast cancer and trastuzumab) and the upcomg data out of duke showing its potential effectiveness in HIV, and you have the potential for a huge blockbuster. Not to mention, the fact that we know bavi was originally designed to take a payload of chemo/radiation, and those conjugates will be up next for testing...and also the animal studies showing that bavi with irradiated dead cancer cells acts like a vaccine against future cancer.